AzTrials
AzTrials

Poly Cystic Ovary SyndromeNCT03713138

Therapeutic Role of Flax Seed for Poly Cystic Ovary Syndrome

A study testing flaxseed powder in people with Poly Cystic Ovary Syndrome, run by Allied Hospital Faisalabad at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study was conducted to determine the therapeutic role of flax seed for Poly cystic ovary syndrome. A sample of 100 subjects were collected. The subjects were from various age group ranging from 18 to 45 years. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Poly Cystic Ovary Syndrome
What is being tested?
flaxseed powder
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 sitePakistan
Study dates
23 Mar 2017to 1 Jan 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • • All females of age 18 to 45 having PCOS
  • Women showing the presence of two out of three features (Oligo- or anovulation, hyper-androgenism, or polycystic ovaries (Ovarian volume >10cc, 12 or more peripherally located follicles 2-9 mm in diameter or hypo-echoic enlarged ovaries with hyper-echoic central stroma in USG)
  • Patients on Metformin (used for insulin resistance)

Who cannot join

  • • Females under 18 and above 45 years of age
  • Those on any other medical therapy
  • Pregnant and lactating women
  • Those with a history of allergy to flaxseed
  • Women on antiplatelet and fibrinolytic drugs
  • Women showing signs of PCOS but showing normal ovaries on ultrasound

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • Allama Iqbal Open University

    Islamabad, Punjab Province, 45710

Other trials in Pakistan

About this study

The study was conducted to determine the therapeutic role of flax seed for Poly cystic ovary syndrome. A sample of 100 subjects were collected. The subjects were from various age group ranging from 18 to 45 years. Subjects showing the signs, symptoms, biochemical, and clinical parameters of the diseases were included in the study. Three different quantities of flax seed were introduced to the subjects for 90 days.

Objectives:

Read more
  1. To assess the nutritional status of Poly cystic Ovary Syndrome patients
  2. To determine the therapeutic role of flax seed for PCOS patients

Material and method: The level of follicle stimulating hormone, leutinizing hormone, sex hormone binding globulin, serum prolactin, ultrasound were analyzed. To determine the side effects of the flax seed, the liver-enzymatic, lipid profile, and renal tests were conducted.

Read the detailed description

Material and methods

Study Population:

The data were collected from the Allied Hospital. All Females of ages 18 to 45 years, having PCOS attending the OPD of Allied Hospital was taken as the study population. Efficacy trials were conducted on the patients of PCOS, including females of age 18-45 years. They were divided into different groups (as per no. of selected treatments along with the control). Ten subjects left the study and were replaced. The project was approved by the ethical review committee.The feeding study was conducted with the cooperation of Allied Hospital. The study protocol was discussed with medical professionals and finalized after through technical suggestions.

Selection of subjects and Study Design

The patients were assorted randomly into four groups, 25 in each, namely control (T0),

A total 100 female subjects were included in the study as under A) Control: To: 25 B) Experimental groups (PCOS): 75

  1. T1: 25
  2. T2: 25
  3. T3: 25

Inclusion Criteria:

All females of age 18 to 45 having PCOS

Women showing the presence of two out of three features (Oligo- or anovulation, hyper-androgenism, or poly cystic ovaries (Ovarian volume >10cc, 12 or more peripherally located follicles 2-9 mm in diameter or hypo-echoic enlarged ovaries with hyper-echoic central stroma in USG). Patients on Metformin (used for insulin resistance)

Exclusion Criteria:

  • Females under 18 and above 45 years of age
  • Those on any other medical therapy
  • Pregnant and lactating women
  • Those with a history of allergy to flax seed
  • Women on anti-platelet and fibrinolytic drugs
  • Women showing signs of PCOS but showing normal ovaries on ultrasound

Study Design

It was literature review based intervention study. The selected population for intervention purposes was studied twice, i.e. before and after the intervention of the selected nutraceutical. The same subjects were studied once again after one month of stopping the intake of selected nutraceutical. The change in results has confirmed the effects of the intervention.

This has been divided into four phases.

  1. Phase-1:Assessment of the nutritional Status in PCOS
  2. Phase -2:Development of nutraceutical (flaxseed sachets)
  3. Phase -3:Intervention to study the effect of selected nutraceutical
  4. Phase-4:Blood Analysis The procedure adopted in each of the above phases is explained as follows: Phase-1: Assessment of the nutritional status of selected patients This was done in Allied Hospital, patients attending OPD of gynecology ward was assessed for nutritional status. Following parameters were studied for this purpose
  • Family History
  • Medical history
  • Physical signs (thyroid gland, height, weight, skin, hair, breasts, belly, and BMI)
  • Menstrual cycle detail (menarche, frequency, duration, and severity)
  • History of dysmenorrhea
  • Ferriman-Gall way scoring for hirsutism
  • Marital status, parity, and difficulty in conception Phase -2: Development of Nutraceutical (flaxseed sachets) Procurement of raw materials Preparation of flax seed powder Preparation of flax seed sachets Phase-3: Intervention An acceptable number of human volunteers were selected keeping in view all ethical considerations. (25 in each group)
  1. Control group (To)
  2. Flaxseed (5 g) xTTS = 15 g/day (T1)
  3. Flaxseed (6.6 g) x TTS = 20 g/day (T2)
  4. Flaxseed (8.3 g) xTTS = 25 g/day (T3) The flaxseed powder from the selected treatments was given daily for a period of 12 weeks. The dietary history of the subjects was monitored with the help of a Food Diary on a weekly basis. Education/counselling were provided to the patients for necessary compliance with the restricted diet for PCOS. Phase-4: Blood Analysis and Ultrasound After three months of intervention blood tests: follicle stimulating hormone (FSH), Luteinizing hormone (LH) thyroid stimulating hormone (TSH), serum prolactin, and ultrasound will be repeated. Biochemical assays Follicles stimulating hormone The blood sample was taken to determine the quantitative level of serum follicles stimulating hormone (FSH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method (ELISA). Luteinizing hormone The blood sample was taken to determine the quantitative level of serum luteinizing hormone (LH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method. Sex hormone binding globulin The serum sex hormone binding globulin hormone (SHBG) in patients fed with flaxseed powder was determined by following the Rosner's method. Prolactin The serum sex prolactin level in patients fed with flaxseed powder was determined by following the radio-immunological method. Thyroid stimulating hormone The thyroid stimulating hormone (TSH) level in patients fed with flaxseed powder was performed to determine the thyroid gland functioning by following the third-generation non-isotopic method. Liver Function Test Alkaline Phosphatase (ALP) The activity of alanine phosphatase in the plasma was determined by using enzyme-linked immune-sorbent assay kit method. Aspartate Aminotransferase (AST) The activity alanine transferase in the plasma was determined by using di-nitrophenyl hydrazine (DNPH) method using Sigma kits 59-50 and 58-50 under the conditions. Alanine Aminotransferase (ALT) The activity alanine aminotransferase in the plasma was determined by using enzyme-linked immune-sorbent assay kit method. Lipid Profile Low-density lipoprotein (LDL) Serum low-density lipoprotein (LDL) was estimated by following the protocol of Vinson. High-density lipoprotein (HDL) The high-density lipoprotein (HDL) was assessed by HDL-Cholesterol precipitation. Triglyceride The triglyceride in the collected serum was determined by liquid triglyceride (GPO-PAP) method. Renal Function Tests Urea The flax seed fed patients were diagnosed with urea content by GLDH method with the help of commercial kit. Creatinine The blood creatinine of the patients fed on flax seed powder was determined by the Jaffe method using creatinine commercial kit. Follicles present in ovaries Ultrasound of the ovaries was carried out to check the number of follicles present in the ovaries. Size of the ovaries The size of the ovaries of patients fed with flax seed powder was also checked in ultrasound. Fasting blood glucose level The blood sample was taken to check the fasting blood glucose level. The sample was taken eight hours after eating. Fasting blood glucose level as determined by glucose dye oxido-reductase mediator reaction which is specific for glucose by glucometer Accuchek active. Research instruments
  5. Questionnaire: For screening/nutritional assessment of PCOS patients
  6. Hormonal analysis: Follicle stimulating hormone (FSH), luteinizing hormone (LH) thyroid stimulating hormone (TSH), Sex Hormone binding globulin (SHBG), and serum prolactin.
  7. Biochemical assay: ALP, ALT, AST, urea, Creatinine, Fasting blood glucose level, LDL, HDL, and triglyceride. Ethical Considerations:Written ethical approval was taken from the management of the concerned hospital and HOD of Gynecology department of the selected hospital. The consent was taken from the subjects after explaining the purpose of the study and after getting their consent for their menstrual cycle history, blood tests and ultrasound. Statistical analysis The data were subjected to statistical analysis by using the SPSS statistical package, analysis of variance (ANOVA) and least significant difference (LSD) was used to determine any significant difference among the treatments at p<0.05.
Being tested
flaxseed powder
Keywords
Follicle stimulating hormone, Leutinizing hormone, Sex hormone binding globulin, Serum Prolactin, Flaxseed sachets, Lipid profile

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • flaxseed powderDietary supplement

    Also called Intervention

    Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.

Study groups in NCT03713138
Study groupRoleWhat they receive
Intervention Flaxseed powderExperimentalThree different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day. Intervention/ Dietary Supplement: Flax seed powder Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day. Other Name: intervention
Receives: Dietary Supplement: flaxseed powder
Control group; Comparison groupNo interventionThe controlled group was given no intervention. No intervention was done to this group. Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Follicle stimulating hormone (mIU/MI)

    The blood sample was taken to determine the quantitative level of serum follicles stimulating hormone (FSH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method (ELISA).

    Measured: 3 months

  2. Leutinizing Hormone (mIU/MI)

    The blood sample was taken to determine the quantitative level of serum luteinizing hormone (LH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method (ELISA-ALPCO)

    Measured: 3 months

  3. Sex hormone binding globulin (mg/dL)

    The serum sex hormone binding globulin hormone (SHBG) in patients fed with flaxseed powder was determined by following the Rosner's method.

    Measured: 3 months

  4. Serum Prolactin (ng/ml)

    The serum sex prolactin level in patients fed with flaxseed powder was determined by following the radio-immunological method.

    Measured: 3 months

Secondary outcomes (2)
  1. blood sugar fasting (mg/dL)

    The blood sample was taken to check the fasting blood glucose level. The sample was taken eight hours after eating. Fasting blood glucose level as determined by glucose dye oxido-reductase mediator reaction which is specific for glucose by glucometer Accuchek active

    Measured: 3 months

  2. Thyroid stimulating hormone (Ml/L)

    The thyroid stimulating hormone (TSH) level in patients fed with flaxseed powder was performed to determine the thyroid gland functioning by following the third-generation non-isotopic method.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2018
  2. Study start23 Mar 2017
  3. Primary completion1 Jan 2018
  4. Study completion1 Jan 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled placebo trial
Masking
Single blind
Who is masked
Participant
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03713138
Sponsor's protocol ID
6099
Status last verified
Oct 2018
First submitted
13 Oct 2018
Last updated
22 Oct 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing flaxseed powder in people with Poly Cystic Ovary Syndrome, run by Allied Hospital Faisalabad at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Follicle stimulating hormone (mIU/MI) (time frame: 3 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2018; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in